文献速递银屑病与炎症性皮肤病

TOPK促进银屑病发展,黄连碱通过抑制TOPK活性缓解银屑病样皮炎

TOPK promotes the development of psoriasis and worenine alleviates psoriasiform dermatitis by inhibiting TOPK activity.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-12-22

本研究探讨TOPK在银屑病发病中的作用,并寻找靶向TOPK的药物。结果发现TOPK在银屑病患者、细胞模型和动物模型中高表达,化学或基因抑制TOPK可减轻M5和咪喹莫特诱导的银屑病样皮炎。黄连碱(worenine)能抑制TOPK激酶活性,并通过该机制缓解银屑病样皮炎,提示TOPK是银屑病防治的潜在药物靶点。

要点

  • TOPK在银屑病患者及模型中的表达升高,提示其参与银屑病发病。
  • 抑制TOPK活性或表达可减轻M5和IMQ诱导的银屑病样皮炎。
  • 黄连碱通过抑制TOPK激酶活性缓解银屑病样皮炎。

核心结论

  • TOPK促进银屑病的发展,是银屑病预防和治疗的潜在药物靶点。
  • 黄连碱通过抑制TOPK活性缓解银屑病样皮炎,为临床干预提供新策略。

研究设计与样本

  • 研究分析银屑病患者、银屑病细胞模型和动物模型中TOPK的表达。
  • 通过化学抑制或基因敲除TOPK,在细胞和动物模型中验证其对银屑病发展的影响。
  • 采用磷酸化蛋白质组学分析TOPK调控的信号通路,并通过体外激酶实验验证黄连碱对TOPK活性的抑制。
  • 最终在细胞和动物模型中验证黄连碱通过抑制TOPK抗银屑病的效果。

主要发现

  • TOPK在银屑病患者、银屑病细胞模型和动物模型中高表达。
  • 化学或遗传抑制TOPK可减轻M5和咪喹莫特(IMQ)诱导的银屑病样皮炎。
  • 黄连碱能抑制TOPK激酶活性。
  • 黄连碱通过抑制TOPK活性缓解M5和IMQ诱导的银屑病样皮炎。

临床怎么用

  • TOPK可能作为银屑病防治的潜在药物靶点。
  • 黄连碱通过抑制TOPK活性缓解银屑病样皮炎,为临床干预提供新思路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is an inflammatory skin disease. The pathogenesis of psoriasis has not been fully elucidated. T-lymphokine-activated killer cell-originated protein kinase (TOPK) activity increases in a proinflammatory environment, and inhibiting TOPK blocks inflammation. However, whether TOPK is involved in the pathogenesis of psoriasis remains to be identified. OBJECTIVES: We aimed to study the role of TOPK in psoriasis and attempted to find a drug targeting TOPK for the prevention and treatment of psoriasis. METHOD: Firstly, the expressions of TOPK in psoriatic patients, psoriatic cell and animal model were analysed by Gene Expression Omnibus database, immunohistochemistry (IHC) staining and western blot (WB). After inhibiting TOPK by chemical or gene knockout, the effect of TOPK on the development of psoriasis was verified in cell and animal model by WB, qRT-PCR, ELISA, haematoxylin-eosin (H&E) and IHC staining. Moreover, phosphoproteomic analysis was performed to explore the signalling pathways regulated by TOPK in the occurrence and development of psoriasis. Then, an in vitro kinase assay was performed to prove TOPK kinase activity was inhibited by worenine. Ultimately, WB, qRT-PCR, ELISA, H&E and IHC staining were used to verify the anti-psoriasis effect of worenine by inhibiting TOPK was in cell and animal model. RESULTS: In this study, we found that TOPK was highly expressed in psoriasis patients, psoriatic cell and animal model, which suggests that TOPK might be associated with psoriasis pathogenesis. Interestingly, chemical or genetic inhibition of TOPK alleviated M5- and imiquimod (IMQ)-induced psoriasis-like dermatitis, which further confirmed the role of TOPK in promoting the development of psoriasis. Moreover, we determined that worenine inhibited TOPK kinase activity. In addition, worenine relieved M5- and IMQ-induced psoriasiform dermatitis by inhibiting TOPK activity. CONCLUSIONS: T-lymphokine-activated killer cell-originated protein kinase promotes the development of psoriasis. Therefore, TOPK might be a promising drug target for the prevention and treatment of psoriasis. Worenine alleviates psoriasiform dermatitis by inhibiting TOPK activity, providing new strategies for clinical intervention.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lu H, Huang Y, Ni X, et al. TOPK promotes the development of psoriasis and worenine alleviates psoriasiform dermatitis by inhibiting TOPK activity. J Eur Acad Dermatol Venereol. 2023. PMID: 38131517. doi:10.1111/jdv.19724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。